No Data
No Data
Express News | Alzamend Neuro Partners With Massachusetts General Hospital for a Phase II Clinical Trial of Al001, a Next‑Generation Lithium Therapeutic Drug Candidate, Involving Patients With Bipolar Disorder
Alzamend Neuro Partners With Mass General for Alzheimer's Treatment Trial
Express News | Alzamend Neuro Partners With Massachusetts General Hospital for a Phase II Clinical Trial of Al001, a Next-Generation Lithium Therapeutic Drug Candidate, Involving Patients With Alzheimer’s Disease
Express News | Alzamend Neuro Shares Are Trading Higher After the Company Announced It Partnered With Massachusetts General Hospital for a Phase II Trial of AL001
EXCLUSIVE: Alzamend Neuro Tells Benzinga 'the Goal Is to Compare Lithium in Human Brain and Brain Structures to Identify a Potentially Ideal Dose of AL001 That Is Safe and Effective as Current Products'
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
No Data